Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could adding warfarin save bypass grafts? new trial investigates.

NCT ID NCT05782270

Disease control Sponsor: China National Center for Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two blood-thinning strategies after a combined heart bypass and endarterectomy procedure. About 202 adults with widespread coronary artery disease will receive either standard dual antiplatelet therapy or that therapy plus warfarin. The goal is to see if adding warfarin keeps the bypass grafts open longer without causing dangerous bleeding.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Warfarin plus dual antiplatelet therapy (aspirin and clopidogrel or ticagrelor)
What this could lead to
If it works, this could point toward a better way to prevent graft failure after complex heart surgery.
What could go wrong
This is a moderate-sized Phase 4 trial, so results may not apply to all patients. Adding warfarin raises bleeding risk, which could outweigh benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 202 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients with diffuse coronary artery disease undergoing CE+CABG during the study period. * No contraindications for both dual antiplatelet therapy and anticoagulation therapy with warfarin. * Must be able to swallow tablets after the surgery. Exclusion Criteria: 1. Patients with high bleeding risk (HAS-BLED ≥ 3); 2. Patients undergoing concomitant aortic valve or mitral valve surgery, or undergoing cardiac surgery for the second time; 3. Emergency surgery; 4. Serum creatinine \>130μmol/L, or significant liver dysfunction (elevated ALT and/or AST); 5. History of digestive or urinary tract bleeding, active gastric bleeding caused by gastric ulcer, or postoperative new-onset gastric bleeding; 6. History of hemorrhagic stroke, or platelet dysfunction; 7. Allergic or with contraindication to any of aspirin, clopidogrel or warfarin; 8. Participated in other clinical trial for drug or device within 30 days; 9. Pregnant or planning to be pregnant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anticoagulation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anticoagulation Coronary endarterectomy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College

    RECRUITING

    Beijing, Beijing Municipality, 100037, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.